Literature DB >> 12814997

The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial.

Gary E Goodman1, Steven Schaffer, Gilbert S Omenn, Chu Chen, Irena King.   

Abstract

beta-Carotene and Retinol Efficacy Trial is a nationwide chemoprevention trial that recruited 18,314 high-risk individuals to test the effect of supplemental beta-carotene and retinol on lung cancer incidence. In this report, we conducted a prospective nested case-control study of the association between serum carotenoids, retinoids, and tocopherols on both lung and prostate cancer incidence. Prerandomization serum samples were selected from 278 lung cancer cases and 205 prostate cancer cases, and 483 controls matched by high-risk population, study center location, age, sex (lung cancer only), smoking status, and year of randomization. Carotenoids, retinoids, and tocopherols were analyzed by high-performance liquid chromatography. Endpoints were confirmed by pathology review (lung cancer) or review of the pathology report (prostate cancer). In the control-only population, there was a significant association between tobacco use and serum micronutrient concentration. Current smokers compared with former smokers had lower mean levels of all of the micronutrients tested with zeaxanthin, beta-cryptoxanthin, alpha-carotene, alpha-tocopherol, retinol, and retinyl palmitate reaching statistical significance at P = 0.05. In the overall population, the mean serum concentrations of all of the micronutrients except gamma-tocopherol were lower for lung cancer cases than controls. Statistically significant trends across quartiles were observed in lutein (P = 0.02), zeaxanthin (P = 0.02), and alpha-tocopherol (P = 0.03). The carotenoid findings in the overall population were because of the strong inverse association between serum micronutrients and lung cancer in females. Statistically significant odds ratios (ORs) comparing 4(th) to 1st quartiles in the female population were seen in lutein [OR, 0.31; confidence interval (CI), 0.13-0.75], zeaxanthin (OR, 0.31; CI, 0.12-0.77), and beta-cryptoxanthin (OR, 0.34; CI, 0.14-0.81). For prostate cancer, mean serum concentrations were lower in cases for all of the nutrients except alpha-carotene. Only for alpha-tocopherol (P(trend) = 0.04) were the findings statistically significant. There was no statistically significant association between serum carotenoids and prostate cancer. Our findings provide additional support for the association between physiological levels of dietary micronutrients and cancer incidence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814997

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  42 in total

1.  Serum selenium and risk of prostate cancer-a nested case-control study.

Authors:  Ulrike Peters; Charles B Foster; Nilanjan Chatterjee; Arthur Schatzkin; Douglas Reding; Gerald L Andriole; E David Crawford; Stefan Sturup; Stephen J Chanock; Richard B Hayes
Journal:  Am J Clin Nutr       Date:  2007-01       Impact factor: 7.045

Review 2.  Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis.

Authors:  J L Rowles; K M Ranard; J W Smith; R An; J W Erdman
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-04-25       Impact factor: 5.554

Review 3.  Novel targets for prostate cancer chemoprevention.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

Review 4.  Are the health attributes of lycopene related to its antioxidant function?

Authors:  John W Erdman; Nikki A Ford; Brian L Lindshield
Journal:  Arch Biochem Biophys       Date:  2008-11-01       Impact factor: 4.013

5.  Expression of the α-tocopherol transfer protein gene is regulated by oxidative stress and common single-nucleotide polymorphisms.

Authors:  Lynn Ulatowski; Cara Dreussi; Noa Noy; Jill Barnholtz-Sloan; Eric Klein; Danny Manor
Journal:  Free Radic Biol Med       Date:  2012-10-16       Impact factor: 7.376

6.  Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Authors:  Demetrius Albanes; Cathee Till; Eric A Klein; Phyllis J Goodman; Alison M Mondul; Stephanie J Weinstein; Philip R Taylor; Howard L Parnes; J Michael Gaziano; Xiaoling Song; Neil E Fleshner; Powel H Brown; Frank L Meyskens; Ian M Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-24

7.  Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival.

Authors:  Joanne L Watters; Mitchell H Gail; Stephanie J Weinstein; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

8.  Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study.

Authors:  Meira Epplein; Adrian A Franke; Robert V Cooney; J Steven Morris; Lynne R Wilkens; Marc T Goodman; Suzanne P Murphy; Brian E Henderson; Laurence N Kolonel; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-16       Impact factor: 4.254

9.  A gamma-tocopherol-rich mixture of tocopherols inhibits chemically induced lung tumorigenesis in A/J mice and xenograft tumor growth.

Authors:  Gang Lu; Hang Xiao; Guang-Xun Li; Sonia C Picinich; Yu-Kuo Chen; Anna Liu; Mao-Jung Lee; Shea Loy; Chung S Yang
Journal:  Carcinogenesis       Date:  2010-01-22       Impact factor: 4.944

10.  Modulatory effects of alpha- and gamma-tocopherols on 4-hydroxyestradiol induced oxidative stresses in MCF-10A breast epithelial cells.

Authors:  Eun-Ju Lee; Seung-Yeon Oh; Mi-Kyung Kim; Sei Hyun Ahn; Byung Ho Son; Mi-Kyung Sung
Journal:  Nutr Res Pract       Date:  2009-09-30       Impact factor: 1.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.